Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.67 - $3.19 $91,897 - $437,540
-137,160 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$2.22 - $3.45 $130,746 - $203,187
58,895 Added 75.25%
137,160 $410,000
Q4 2021

Feb 14, 2022

BUY
$2.36 - $3.57 $184,705 - $279,406
78,265 New
78,265 $207,000
Q3 2021

Nov 15, 2021

SELL
$3.5 - $4.5 $92,400 - $118,800
-26,400 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$3.09 - $4.54 $81,576 - $119,856
26,400 New
26,400 $115,000
Q4 2020

Feb 11, 2021

SELL
$2.35 - $3.74 $54,990 - $87,516
-23,400 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$1.78 - $4.13 $41,652 - $96,642
23,400 New
23,400 $56,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.